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ABSTRACT
Objective: To estimate the cost-effectiveness (CE) of total body hypother-
mia plus intensive care versus intensive care alone to treat neonatal
encephalopathy.
Methods: Decision analytic modeling was used to synthesize mortality
and morbidity data from three randomized controlled trials, the Total
Body Hypothermia for Neonatal Encephalopathy Trial (TOBY), National
Institute of Child Health and Human Development (NICHD), and
CoolCap trials. Cost data inputs were informed by TOBY, the sole source
of prospectively collected resource utilization data for encephalopathic
infants. CE was expressed in terms of incremental cost per disability-free
life year (DFLY) gained. Probabilistic sensitivity analysis was performed to
generate CE acceptability curves (CEACs).
Results: Cooling led to a cost increase of £3787 (95% conﬁdence interval
[CI]: -2516, 12,360) (€5115; 95% CI: -3398–16,694; US$5344; 95% CI:
-3598, 26,356; using 2006 Organisation for Economic Co-operation and
Development (OECD) purchasing power parities) and a DFLY gain of
0.19 (95%CI: 0.07–0.31) over the ﬁrst 18 months after birth. The incre-
mental cost per DFLY gained was £19,931 (€26,920; US$28,124). The
baseline CEAC showed that if decision-makers are willing to pay £30,000
for an additional DFLY, there is a 69% probability that cooling is cost-
effective. The probability of CE exceeded 99% at this threshold when the
throughput of infants was increased to reﬂect the national incidence of
neonatal encephalopathy or when the time horizon of the economic evalu-
ation was extended to 18 years after birth.
Conclusions: The probability that cooling is a cost-effective treatment for
neonatal encephalopathy is ﬁnely balanced over the ﬁrst 18 months after
birth but increases substantially when national incidence data or an
extended time horizon are considered.
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Introduction
The incidence of neonatal encephalopathy has been estimated at
between one and four per 1000 term live births in the developed
world, with adverse outcomes ranging from death to severe
cerebral palsy and neurodevelopmental impairment [1,2]. New
interventions are urgently needed to improve the outcome of
infants with neonatal encephalopathy, but it is important to
understand the cost-effectiveness (CE) of these interventions
before widespread implementation. Recent studies and system-
atic reviews have suggested that reducing body temperatures
3–5°C below normal is safe and improves neurological function
[3–12]; a recent meta-analysis found that therapeutic hypother-
mia resulted in a clinically important reduction in the combined
outcome of mortality or major neurodevelopmental disability at
18 months of age (typical relative risk [RR] 0.76; 95% conﬁ-
dence interval [CI] 0.65–0.89) [8]. Nevertheless, none of the
studies included in these reviews or the meta-analysis incorpo-
rated CE outcomes. We now report a health-care CE study that
used outcomes data from three randomized controlled trials, the
Total Body Hypothermia for Neonatal Encephalopathy Trial
(TOBY) [13], and the National Institute of Child Health and
Human Development (NICHD), and CoolCap trials [14,15];
health service cost data were obtained from TOBY, the sole
source of prospectively collected resource utilization data for
encephalopathic infants.
Methods
Economic Model
A decision analytic model was constructed to estimate the incre-
mental CE of intensive care plus cooling versus intensive care
alone for the treatment of moderate to severe neonatal encepha-
lopathy. The time horizon of the baseline model was the ﬁrst 18
months after birth. In the ﬁrst 12 months after birth, each infant
could transition to either survival with unconﬁrmed neurological
function or death; in the period 12 months to at least 18 months,
surviving infants could transition to one of three mutually exclu-
sive health states: survival without neurological abnormality,
survival with neurological abnormality, or death. Incremental
costs (DC) were measured from the British National Health
Service (NHS) health care and personal social services perspec-
tive [16], and incremental effectiveness (DE) was measured in
terms of disability-free life years (DFLYs) gained [17]. The
primary outcome of the economic evaluation was the incremen-
tal CE ratio (ICER; DC/DE). Costs and effects were discounted at
a rate of 3.5% per year as recommended by the National Insti-
tute for Health and Clinical Excellence [16].
Transition Probabilities to the Health States
The proportion of children in each health state during each time
period was obtained from the three randomized controlled trials
of therapeutic hypothermia for the treatment of neonatal
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encephalopathy, namely our own recently completed TOBY trial
[13], and the NICHD and CoolCap trials [14,15]. Data synthesis
for the transition probabilities was used because the sample size
calculation for the TOBY trial was not based on the requirements
of the economic evaluation; ex post sample size calculations
suggested that TOBY did not have sufﬁcient power for the ICER.
We therefore elected to incorporate all available evidence appro-
priate for informing costs and the DFLY.
In brief, the TOBY trial randomized 325 infants less than 6
hours of age and a gestational age of at least 36 weeks with
neonatal encephalopathy and abnormal amplitude integrated
electroencephalography (aEEG) to intensive care plus total body
cooling for 72 hours (n = 163) or intensive care alone (n = 162).
The primary outcome for TOBY was the combined 18-month
outcome of mortality or severe neurodevelopmental disability
deﬁned as Bayley Mental Developmental Index [18] (MDI) <70,
Gross Motor Function Classiﬁcation Score [19] (GMFCS) 3 to 5,
or bilateral cortical visual impairment with no useful vision.
NICHD randomized 208 infants with neonatal encephalopathy
to intensive care plus total body cooling (for 72 hours; n = 102)
or intensive care without cooling (n = 106); the primary outcome
was death or moderate or severe disability (moderated disability
deﬁned as having one of: MDI 70–84, GMFCS of 2, hearing
deﬁcit with ampliﬁcation, or a seizure disorder; severe disability
was deﬁned as: <70 on the Bayley MDI, GMFCS 3–5, or bilateral
blindness or deafness) at 18 months of age. The CoolCap trial
randomized 234 encephalopathic infants to intensive care plus
head cooling (for 72 hours; n = 116) or intensive care without
cooling (n = 118) and used a primary outcome of combined
frequency of mortality and severe neurodevelopmental disability
(deﬁned using GMFCS 3–5, Bayley MDI < 70, or bilateral corti-
cal visual impairment) at 18 months of age. We synthesized the
data from these three trials using a Bayesian approach to meta-
analysis where the outcomes data from the NICHD and CoolCap
trials were treated as prior information to the TOBY trial likeli-
hood data for each period in the model (10–12 months; 12–18
months). If the required data could not be obtained directly from
the NICHD or CoolCap trial publications [14,15], the investiga-
tors from both trials provided the required information.
Measurement and Valuation of Resource Utilization
and Costs
The TOBY trial had been designed to incorporate a prospective
economic evaluation and to our knowledge, provided the sole
source of prospectively collected and validated resource utiliza-
tion data for total body cooling for encephalopathic infants. The
data on resources used, including personnel, were collected
during transport to/from a cooling hospital and throughout the
hospital stay. Each infant’s clinical course was classiﬁed by four
mutually exclusive levels of neonatal care as deﬁned by the
British Association of Perinatal Medicine [20].
Data on hospital readmissions, outpatient hospital visits, and
the use of other health-care services after discharge were
obtained from information gathered at the TOBY 18-month
clinical follow-up assessment and was supplemented by question-
naires completed by parents at 6, 12, and 18 months. Any
missing data on resource utilization were imputed using the ICE
multiple imputation program in Stata version 10 (StataCorp,
College Station, TX).
Unit costs were attached to each resource utilization item to
obtain a cost per child for each health state. The cost per level of
neonatal care was obtained from the NHS Reference Costs data-
base [21], and drug costs were from the British National Formu-
lary [22]. The cost associated with infant death was derived from
previously published observational research conducted at our
research unit [17].
In TOBY, costs that were speciﬁc to total body cooling
included the capital costs of the aEEG machine and the Teco-
therm total body cooling system (Tecotherm, TS Medical 200M,
Tec-Com, Halle, Germany). Noncapital costs associated with
these machines were obtained via telephone interviews with the
UK suppliers of the cooling equipment (Inspiration Health Care
UK) or from UK TOBY centers. The cost of each machine was
annuitized over 5 years using equivalent annual costing and a
discount rate of 3.5%. The cost of aEEG and total body cooling
was calculated by dividing the equivalent annual cost of the
machines by the number of infants per year who received total
body cooling in each TOBY participating center. The baseline
model therefore distributed the cost of the intervention across the
163 infants cooled in 42 participating TOBY centers (an average
of 1.7 infants per center per year was cooled in TOBY centers).
All costs are in pound sterling valued at 2006 to 2007 prices.
Measurement of Effectiveness
The effectiveness measure was the DFLY metric [17]. This end-
point is similar to a clinical endpoint of survival without neuro-
logical abnormality except that it accounts for the duration spent
in the health state. We deﬁned survival without neurological
abnormality as Bayley MDI > 84, Bayley psychomotor develop-
ment index (PDI) > 84, no neuromotor impairment, normal
vision, and normal hearing [13]. Children without a neurological
abnormality were assigned a health state value of 1 for each
disability-free year of survival. Children with neurodevelopmen-
tal abnormalities or who died were assigned a health state value
of 0.
Statistical Analysis
The decision model was analyzed using TreeAge Pro (TreeAge
Pro Inc, 2008; TreeAge Software, Williamstown, MA). A number
of sensitivity analyses informing different scenarios important to
decision-makers and hospital planners were conducted to assess
their effect on the ICER. The number of infants treated in each
neonatal unit under controlled conditions during the TOBY trial
may differ from current or future practice. The cost per infant per
center per year for aEEG and total body cooling was therefore
varied assuming: 1) patient throughput reﬂected current practice
in the UK Cooling Register (mean (SD) of 7.1 (4.5) infants per
center per year across 28 centers) and 2) patient throughput
reﬂected the national incidence of neonatal encephalopathy dis-
tributed across the current conﬁguration of neonatal services
(calculated at 15 infants per tertiary level neonatal unit per year).
One major trial has conducted cooling without the use of aEEG
[15]; alternatively, some units already provide this service. The
cost per infant for the cooling equipment was therefore calcu-
lated excluding the cost of the aEEG machine. The time horizon
of the baseline model was extended to 18 years of age using
gestation and disability status-speciﬁc data generated from a
study by Mangham et al. [23].
Probabilistic sensitivity analysis was conducted for each of
these analyses. A beta distribution was assigned to the prior and
likelihood data for transition probabilities based on binomial
data; the Dirichlet distribution was assigned to the prior and
likelihood data for transition probabilities based on multinomial
data [24]. For costs, the gamma distribution was assumed for all
variables except the cost per infant of aEEG and total body
cooling. These costs were bootstrapped because they did not
follow a convenient distribution [25]. Nonparametric bootstrap-
ping was also used for the uncertainty surrounding the time spent
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in the ﬁnal health state because TOBY follow-up varied between
children. To propagate the uncertainty throughout the model,
Monte Carlo simulation was used and 10,000 draws from the
input distributions was speciﬁed. The joint uncertainty of cost
and effectiveness was represented using the CE plane and CE
acceptability curves (CEACs) [26]. Statements about CE are
based on notional willingness to pay thresholds held by decision-
makers of £20,000 per DFLY gained and £30,000 per DFLY
gained [16].
Results
Model Inputs
Mean resource use inputs and their unit costs are summarized in
Table 1. The costs and transition probabilities associated with
the health states in the decision model are shown in Table 2. The
estimated mean cost of cooling was £5918 (95% CI 1347–
14,304). The mean hospital cost to initial discharge for survivors
was £12,441 (95% CI 10,331–14,772) in the cooled group and
£12,728 (95% CI 10,553–15,108) in the noncooled group. For
those infants who died before discharge, the mean cost per infant
was £5315 (95% CI 4445–6233) in the cooled group and £7637
(95% CI: 5707–9765) in the noncooled group. The probability
of an infant surviving to 12 months was 0.74 (95% CI 0.70–
0.79) in the cooling group and 0.70 (95% CI 0.65–0.74) for the
noncooled group.
Also in Table 2 are the model inputs for the 12- to 18-month
period. The probability of surviving without neurological abnor-
mality was 0.47 (95% CI 0.41–0.52) and 0.32 (95% CI 0.27–
0.38) in the cooled and noncooled groups, respectively. The
probability of survival from 12 to 18 months with neurological
abnormality or death was 0.52 (95% CI 0.46–0.58) and 0.01
(95% CI 0.00–0.03), respectively, in the cooling group. For the
noncooled group, the probability of survival with neurological
abnormality or death over this period was 0.64 (95% CI 0.59–
0.70) and 0.03 (95% CI 0.01–0.05), respectively.
Health service costs over the 12- to 18-month period differed
depending on the neurological status of the child. For those
children categorized as having no neurological abnormality,
mean hospital inpatient costs were £124 (95% CI 42–254) for
the cooled group and £129 (95% CI 29–306) for the noncooled
group. For those children categorized as having a neurological
abnormality, the mean inpatient costs for those in the cooled
versus not cooled groups were estimated at £1578 (95% CI
606–2995) and £1105 (95% CI 372–2248), respectively.
CE of Therapeutic Hypothermia
The costs and effects of intensive care plus cooling and intensive
care without cooling are presented in Table 3. Over the ﬁrst 18
months after birth, the mean health service cost was £22,324
(95% CI 16,782–30,738) in the cooled group and £18,537 (95%
CI 16,062–21,224) in the noncooled group. The mean incremen-
tal cost associated with cooling was £3787 (95% CI -2516–
12,360). As depicted on the CE plane in Figure 1, a number of
bootstrap replicates predicted that cooling would result in cost
savings (15% of the incremental cost draws were negative). The
mean number of DFLYs was estimated at 0.54 (95% CI 0.49–
0.64) and 0.35 (95% CI 0.28–0.42) for the cooled and non-
cooled groups, respectively. Cooling resulted in an additional
0.19 (95% CI 0.07–0.31) DFLYs over the ﬁrst 18 months after
birth.
Table 1 Resource use values and unit costs of resource items (£ sterling 2006–2007 prices)
Resource use variable
Cooling group Standard care group
Unit cost (£)*mean resource use (SE) mean resource use (SE)
Resource use of inpatient stay§ (days)
Intensive care (level 1) 5.45 (0.41) 4.76 (0.35) 938†
High dependency care (level 2) 2.67 (0.73) 3.19 (0.91) 671†
Special care (level 3) 7.14 (0.87) 9.13 (1.04) 405†
Ordinary care (level 4) 2.87 (0.63) 3.00 (0.80) 267†
Readmission after initial discharge** 0.84 (0.13) 0.95 (0.17) 480 or 1833†#
Resource use of additional investigations||
X-rays 2.12 (0.21) 1.92 (0.20) 31†
Ultrasound scans 3.20 (0.10) 3.83 (0.14) 56†
ECGs 0.38 (0.05) 0.46 (0.66) 35†
MRIs 0.72 (0.035) 0.76 (0.397) 239†
Resource use associated with transfer¶
Transfer 0.94 (0.06) 0.94 (0.06) 257†
Consultant 0.21 (0.05) 0.26 (0.05) 103‡
Registrar 0.48 (0.06) 0.54 (0.07) 57‡
Nurse grade D & E 0.14 (0.04) 0.10 (0.08) 42‡
Nurse grade F 0.16 (0.04) 0.32 (0.08) 62‡
Nurse grade G & I 0.23 (0.05) 0.14 (0.04) 72‡
Community resource use** (visits)
General practitioner visit 7.25 (0.99) 7.34 (1.27) 34‡
Health visitor visit 10.72 (1.31) 11.87 (2.14) 36‡
Practice nurse visit 2.68 (0.38) 2.58 (0.69) 30‡
Community nurse visit 3.52 (1.29) 5.81 (1.96) 63‡
Community pediatrician visit 2.25 (0.51) 2.43 (0.62) 58‡
Physiotherapist visit 8.17 (2.08) 13.76 (2.23) 40‡
Social worker visit 0.95 (0.38) 1.24 (0.37) 39‡
*Source:
†National Schedule of Reference Costs.
‡Personal Social Services Research Unit.
§Measured in days of care until initial discharge, where <9.5% of values were missing.
||Resource use until initial discharge where <30% of values were missing.
¶Resource use until discharge where <4% of values were missing.
#£480 for standard bed day and £1833 if ventilation was required.
**Resource use over 18 months.
ECG, electrocardiogram; MRI, magnetic resonance imaging.
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The ICER was calculated at £19,931 per DFLY gained in the
baseline analysis. The uncertainty surrounding the ICER is sum-
marized on the CE plane (Fig. 1) and by using the CEAC (Fig. 2),
which plots the probability that cooling is cost-effective at dif-
ferent willingness to pay thresholds (l) for a DFLY gain. Figure 1
shows there is substantial uncertainty surrounding the ICER, and
by extension, it is uncertain if cooling is cost-effective. The CEAC
in Figure 2 (top left panel) shows the exact probabilities of CE
for cooling at alternative values of l. If l is £30,000, there is a
69% probability that total body cooling is cost-effective; if
l = £20,000, the probability of CE is 52%.
Sensitivity Analyses
The sensitivity analyses are presented in Table 3. Sensitivity
analyses 1 and 2 varied the number of infants undergoing cooling
at each hospital. When the number of infants per center per year
reﬂected current data from the UK Cooling Register, cooling was,
on average, cost-saving (£-295; 95% CI -4555–5414), cooling
dominated standard care (on average, less costly and more effec-
tive), and there was a 92% probability that cooling is cost-
effective at l = £20,000 (upper right panel, Fig. 2). If 15 infants
were cooled per center per year, cooling was again cost-saving
(£-1708; 95% CI -5251–1730). The CEAC demonstrated when
l = £7,100, there was a 95% probability that cooling is cost-
effective under this scenario (Fig. 2, middle left panel). The third
scenario excluded the cost of the aEEG machine. The incremental
cost of cooling was £601 (95% CI -3811–5584) and the ICER
was £3163 per DFLY gained. If l = £30,000, there was a 95%
probability that cooling is cost-effective under this scenario
(Fig. 2, middle right panel). Sensitivity analysis 4 extended the
baseline model to a time horizon of 18 years; the estimated model
inputs (transition probabilities and costs) are presented in
online Appendix 1 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i6_Regier.asp. The incremental effec-
tiveness of cooling over 18 years was 1.30 DFLYs gained (95%
CI 0.51–2.15), and the incremental cost was £1847 (95% CI
-4494–10,303). The ICER was £1421 per DFLY gained and
there was a 99% probability that cooling is cost-effective if
l = £20,000 (Fig. 2, lower left panel). Therapeutic hypothermia
had a 95% probability of being cost-effective if l = £8300.
Conclusion
This study used decision modeling to synthesize clinical out-
comes from three randomized controlled trials that examined
therapeutic hypothermia for infants with moderate or severe
neonatal encephalopathy; the health service costs associated with
hypothermia or normothermia were obtained from TOBY, which
Table 2 Estimated model parameter inputs
Parameter
Mean (95% CI)
cooling group
Mean (95% CI) standard
care group Distribution†
First 12 months: transition probabilities and costs
Survival with unconﬁrmed neurological function 0.74 (0.70–0.79) 0.70 (0.65–0.74) Beta(281,98)‡
Beta(270,116)§
Death 0.26 (0.21–0.30) 0.30 (0.25–0.35) Beta(98,281)‡
Beta(116,270)§
Cost of cooling equipment and aEEG* in £ 5,918 (1,347–14,304) N/A Uniform (nonparametric bootstrap)
Cost of transfer in £ 147 (123–175) 144 (119–172) Gamma(122.35,0.829)‡
Gamma(111.08,0.769)§
Hospital costs to discharge for survivors in £ 12,441 (10,331–14,772) 12,728 (10,553–15,108) Gamma(123.48,0.009)‡
Gamma(118.98,0.009)§
Hospital costs for nonsurvivors in £ 5,315 (4,445–6,233) 7,637 (5,707–9,765) Gamma(132.09,0.025)‡
Gamma(54.87,0.007)§
Inpatient costs post discharge in £ 1,086 (628–1,661) 2,397 (1,140–4,013) Gamma(16.25,0.015)‡
Gamma(2404.65,0.004)§
Community care costs post discharge to 6 months in £ 681 (556–816) 713 (552–897) Gamma(102.01,0.15)‡
Gamma(63.46,0.089)§
Community care costs 6 to 12 months 440 (304–1,601) 684 (436–994) Gamma(33.58,0.676)‡
Gamma(23.42,0.034)§
12 to 18 months: transition probabilities and costs
Age assessed 1.54 (1.41–1.72) 1.64 (1.51–1.86) Uniform (nonparametric bootstrap)
Survival without neurological abnormality 0.47 (0.41–0.52) 0.32 (0.27–0.38) Dirichlet(a1 = 132)‡
Dirichlet(a1 = 87)§
Survival with neurological abnormality 0.52 (0.46–0.58) 0.64 (0.59–0.70) Dirichlet(a2 = 147)‡
Dirichlet(a2 = 175)§
Death 0.01 (0–0.03) 0.03 (0.01–0.05) Dirichlet(a3 = 4)‡
Dirichlet(a3 = 8)§
Inpatient costs, children without neurological abnormality in £ 124 (42–254) 129 (29–306) Gamma(5.20,0.011)‡
Gamma(5.32,0.024)§
Inpatient costs, children with neurological abnormality in £ 1,578 (606–2,995) 1,105 (372–2,248) Gamma(5.32,0.005)‡
Gamma(6.55,0.004)§
Community care costs, children without neurological
abnormality in £
217 (119–342) 214 (113–348) Gamma(14.48,0.067)‡
Gamma(12.98,0.061)§
Community care costs, children with neurological
abnormality in £
338 (178–553) 459 (260–709) Gamma(12.63,0.038)‡
Gamma(15.98,0.035)§
Death in £ 1,623 (1,308–1,941) 1,623 (1,308–1,941) Gamma(93.78,0.0578)‡,§
*Expected cost per cooled infant per year in each trial center (n = 163): inclusive of ﬁxed costs for aEEG and cooling machines amortized over 5 years, the cost of maintaining the cooling
equipment, and variable costs.
†All distributions follow the parameterization documented by TreeAge Pro (2008) software, except that of the beta distribution which was parameterized in terms of Beta(a,b), where
a = number of events, r, and b = n - r when n is the sample size.
‡Distribution parameters for the cooling group.
§Distribution parameters for the standard care group.All costs are reported in 2006–2007 £ sterling.
aEEG, ampliﬁed EEG; N/A, not applicable.
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Table 3 Cost-effectiveness results and sensitivity analyses
Parameter
Mean (95% CI)
cooling group
Mean (95% CI) standard
care group Mean difference* (95% CI)
Baseline analysis
Cost in £ 22,324 18,537 3,787
(16,782–30,738) (16,062–21,224) (-2,516–12,360)
Effectiveness 0.54 0.35 0.19
(0.49–0.64) (0.28–0.42) (0.07–0.31)
ICER £19,931 per DFLY gained
l = 20,000 52% probability that cooling is cost-effective
l = 30,000 69% probability that cooling is cost-effective
Sensitivity analysis 1: number of infants per center per year cooled informed using the UK Cooling Register
Cost in £ 18,242 18,537 -295
(15,214–23,559) (16,062–21,224) (-4,555–5,414)
Effectiveness 0.54 0.35 0.19
(0.49–0.64) (0.28–0.42) (0.07–0.31)
ICER On average, cooling dominates standard care
l = 20,000 92% probability that cooling is cost-effective
l = 30,000 96% probability that cooling is cost-effective
Sensitivity analysis 2: 15 infants per center per year require cooling
Cost in £ 16,829 18,537 -1,708
(14,578–19,224) (16,062–21,224) (-5,251–1,730)
Effectiveness 0.54 0.35 0.19
(0.49–0.64) (0.28–0.42) (0.07–0.31)
ICER On average, cooling dominates standard care
l = 7,100 95% probability that cooling is cost-effective
l = 20,000 99% probability that cooling is cost-effective
Sensitivity analysis 3: aEEG cost excluded
Cost in £ 19,419 18,537 601
(16,228–23,736) (16,062–21,224) (-3,811–5,584)
Effectiveness 0.54 0.35 0.19
(0.49–0.64) (0.28–0.42) (0.07–0.31)
ICER £3,163 per DFLY gained
l = 20,000 88% probability that cooling is cost-effective
l = 30,000 95% probability that cooling is cost-effective
Sensitivity analysis 4: baseline analysis extended to 18 years
Cost in £ 30,719 28,872 1,847
(24,460–39,048) (25,224–32,747) (-4,944–10,303)
Effectiveness 7.75 6.45 1.30
(5.84–9.50) (4.58–8.15) (0.51–2.15)
ICER £1,421 per DFLY gained
l = 8,300 95% probability that cooling is cost-effective
l = 20,000 99% probability that cooling is cost-effective
*The mean of the standard care group is subtracted from the mean of the cooling group.The probability of cost-effectiveness at l = £20,000 and l = £30,000 was reported unless there was
a 95% probability of cost-effectiveness at a l £20,000.All costs are reported in 2006–2007 £ sterling.
aEEG, ampliﬁed EEG; DFLY. disability-free life year; ICER, incremental cost-effectiveness ratio; l, willingness to pay threshold held by decision-makers for an additional DFLY.
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tiveness of each of the 10,000 simulated cost-
effectiveness ratios (baseline analysis).
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to our knowledge is the sole source of prospectively collected
resource use data for encephalopathic infants. Although the
TOBY trial could inform a prospective economic evaluation, we
used decision modeling to facilitate data synthesis because none
of the published randomized controlled trials have provided con-
clusive proof of efﬁcacy. Further, TOBY was not powered to
detect statistically signiﬁcant differences in our effectiveness
outcome: the DFLY. We therefore sought to incorporate all avail-
able evidence with a view to inform decision-makers as to the CE
of therapeutic hypothermia [27].
We found that therapeutic hypothermia resulted in increased
costs and effectiveness over the ﬁrst 18 months after birth.
Within the current decision-making context of the British NHS
(ICER £30,000), and considering the commonly cited willing-
ness to pay a threshold of US$50,000 and €30,000 for an effec-
tiveness gain, the baseline ICER of £19,931 (US$28,124;
€26,290; using 2006 Organisation for Economic Co-operation
and Development (OECD) purchasing power parities) per DFLY
gained suggested that cooling may offer good value for money
[16,28]. Nevertheless, the probabilistic sensitivity analysis
revealed that there is sufﬁcient uncertainty surrounding the base-
line ICER. This is evident when examining the CEAC, which
demonstrated that there is a 69% probability that cooling is
cost-effective when decision-makers’ willingness to pay threshold
was £30,000 for a DFLY gain. The probability that cooling was
cost-effective fell to 52% when l = £20,000. The CE of cooling
is therefore ﬁnely balanced over the ﬁrst 18 months after birth.
The sensitivity analyses examined how the ICER differed
across critical assumptions important to decision-makers and
hospital planners. When the number of infants cooled per year
reﬂected current data from the UK Cooling Register, cooling, on
average, dominated standard care, and there was a 92% prob-
ability that cooling is cost-effective if l = £20,000 and a 96%
probability of CE when l = £30,000. Future analyses should
assess the efﬁciency balances between the numbers of centers
offering cooling, the throughput of infants in each center, and the
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Figure 2 Cost-effectiveness acceptability curve
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numbers of transfers required if smaller or larger cooling centers
are adopted as policy.
Therapeutic hypothermia was also cost-effective when the
baseline model was extended to a time horizon of 18 years
because the ICER was £1421, and there was a 95% probability
that cooling was cost-effective if l = £8300. Consequently, the
totality of evidence seems to favor the adoption of cooling into
routine clinical practice. Nevertheless, local conﬁgurations of
neonatal services and future levels of demand for cooling should
be considered when interpreting the study ﬁndings.
Although this economic evaluation was conducted according
to current methodological guidelines [16,29], there are a number
of caveats. First, the effectiveness of cooling was not measured in
terms of the quality adjusted life years (QALY) metric currently
recommended to inform resource allocation decisions [16]. The
QALY metric was not used because of methodological concerns
surrounding the use of preference-based measurement in early
childhood [30]. The DFLY metric was used instead of the QALY
approach [17]. The limitation of the DFLY metric is that it does
not distinguish between varying levels of disability likely to have
different utilities attached to them. The DFLY assumption can be
considered conservative in this context because those in the non-
cooled group of TOBY were shown to have a higher incidence of
moderate to severe neurodevelopmental disability [13]. Never-
theless, there is a need for further research developing preference-
based instruments in early childhood.
Second, we excluded the costs borne by other sectors of the
economy, for example, costs borne by parents or informal car-
egivers, the cost of education services, or medical–legal costs.
Incorporation of these wider societal costs may reduce the ICER
given the additional clinical burden of neurological abnormality
(and by extension, economic burden) in the noncooled group.
Finally, our sensitivity analysis extending the time horizon to 18
years was informed by cohort data. Future research will use data
from the TOBY 7-year follow-up study to validate these data
inputs.
In conclusion, we show that the CE of therapeutic hypother-
mia for treating moderate to severe neonatal encephalopathy is
ﬁnely balanced over the ﬁrst 18 months after birth because there
was a 69% probability that cooling is cost-effective when
l = £20,000. The probability of CE increases substantially over
an extended time horizon because the probability of CE reached
95% at a willingness to pay threshold of £8300 for a DFLY gain.
These data should aid local decisions on the likely economic
impact of implementation of this intervention.
Source of ﬁnancial support: None.
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